Last reviewed · How we verify
Vivitrol
At a glance
| Generic name | Vivitrol |
|---|---|
| Also known as | XR-NTX, intramuscular injection of Vivitrol 380 mg, long-acting injectable naltrexone, Naltrexone Injectable Product, depot naltrexone (380 mg) |
| Sponsor | New York State Psychiatric Institute |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- The Safety and Efficacy of Naltrexone and Scopolamine Utilized in Combination in the Treatment of Major Depression: A Double Blinded, Randomized, Controlled Pilot Study (Phase 4)
- Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19 (Phase 2)
- Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry (Phase 4)
- The Impact of the Opiate Antagonist Naltrexone on the Emotional Valence of Dreams (Phase 4)
- Lofexidine: Enhancing Naltrexone Treatment for Opiate Addiction (Phase 2)
- Phase 1, Single-dose, Double-blind, Rand., Placebo- and Active-controlled, 4-period, 4-sequence Crossover, Proof-of-Concept Study to Evaluate Effect of Naltrexone on Abuse Potential of Methylphenidate (Phase 1)
- Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis (Phase 2)
- Screening Medications for Cocaine Cessation and Relapse Prevention (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vivitrol CI brief — competitive landscape report
- Vivitrol updates RSS · CI watch RSS
- New York State Psychiatric Institute portfolio CI